Capstone Therapeutics Corp. (CAPS)
USD 2.08
(-11.49%)
USD 2.08
(-11.49%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.81 Million USD | -264.97% |
| 2022 | 2.31 Million USD | -40.96% |
| 2021 | 3.92 Million USD | -62.5% |
| 2020 | 10.45 Million USD | 604.34% |
| 2019 | -2.07 Million USD | -445.53% |
| 2018 | -380 Thousand USD | 78.35% |
| 2017 | -1.75 Million USD | -164.71% |
| 2016 | -663 Thousand USD | 76.07% |
| 2015 | -2.77 Million USD | 33.5% |
| 2014 | -4.16 Million USD | -6.27% |
| 2013 | -3.92 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -381 Thousand USD | 65.77% |
| 2024 Q1 | -1.11 Million USD | 44.87% |
| 2023 Q1 | -1.11 Million USD | -132.57% |
| 2023 Q3 | -609 Thousand USD | -690.91% |
| 2023 Q2 | -77 Thousand USD | 93.09% |
| 2023 FY | -3.81 Million USD | -264.97% |
| 2023 Q4 | -2.01 Million USD | -231.53% |
| 2022 Q1 | -183 Thousand USD | -125.49% |
| 2022 Q4 | -479 Thousand USD | -135.4% |
| 2022 Q3 | 1.35 Million USD | -16.69% |
| 2022 FY | 2.31 Million USD | -40.96% |
| 2022 Q2 | 1.62 Million USD | 987.43% |
| 2021 Q1 | -1.84 Million USD | -123.1% |
| 2021 Q4 | 718 Thousand USD | -35.66% |
| 2021 Q3 | 1.11 Million USD | -29.46% |
| 2021 FY | 3.92 Million USD | -62.5% |
| 2021 Q2 | 1.58 Million USD | 185.84% |
| 2020 FY | 10.45 Million USD | 604.34% |
| 2020 Q3 | 667 Thousand USD | 0.0% |
| 2020 Q4 | 7.98 Million USD | 1096.4% |
| 2019 FY | -2.07 Million USD | -445.53% |
| 2019 Q1 | -855 Thousand USD | -126.19% |
| 2019 Q2 | -668 Thousand USD | 21.87% |
| 2018 Q2 | 1.27 Million USD | 317.72% |
| 2018 Q1 | -587 Thousand USD | -4.08% |
| 2018 Q3 | -693 Thousand USD | -154.23% |
| 2018 FY | -380 Thousand USD | 78.35% |
| 2018 Q4 | -378 Thousand USD | 45.45% |
| 2017 Q1 | -387 Thousand USD | -9.63% |
| 2017 FY | -1.75 Million USD | -164.71% |
| 2017 Q3 | -598 Thousand USD | -190.29% |
| 2017 Q2 | -206 Thousand USD | 46.77% |
| 2017 Q4 | -564 Thousand USD | 5.69% |
| 2016 Q1 | -379 Thousand USD | 56.34% |
| 2016 Q2 | -390 Thousand USD | -2.9% |
| 2016 Q4 | -353 Thousand USD | -176.91% |
| 2016 FY | -663 Thousand USD | 76.07% |
| 2016 Q3 | 459 Thousand USD | 217.69% |
| 2015 Q3 | -435 Thousand USD | 42.15% |
| 2015 Q4 | -868 Thousand USD | -99.54% |
| 2015 Q1 | -716 Thousand USD | -37.69% |
| 2015 Q2 | -752 Thousand USD | -5.03% |
| 2015 FY | -2.77 Million USD | 33.5% |
| 2014 Q1 | -1.02 Million USD | -42.94% |
| 2014 Q2 | -1.39 Million USD | -36.11% |
| 2014 Q4 | -520 Thousand USD | 57.86% |
| 2014 Q3 | -1.23 Million USD | 11.29% |
| 2014 FY | -4.16 Million USD | -6.27% |
| 2013 Q2 | -1 Million USD | -1.31% |
| 2013 Q1 | -995 Thousand USD | 0.0% |
| 2013 Q4 | -715 Thousand USD | 40.52% |
| 2013 FY | -3.92 Million USD | 0.0% |
| 2013 Q3 | -1.2 Million USD | -19.25% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -185.975% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 45.309% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 107.209% |
| Nascent Biotech, Inc. | -2.08 Million USD | -82.93% |
| Rebus Holdings, Inc. | -1.02 Million USD | -274.412% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 105.863% |
| Qrons Inc. | -789.34 Thousand USD | -383.818% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -503.883% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 93.899% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -819.18% |
| Skye Bioscience, Inc. | -37.64 Million USD | 89.855% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 94.905% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 41.926% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1296.844% |
| SQZ Biotechnologies Company | -79.46 Million USD | 95.194% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -32.036% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -109.774% |
| Mesoblast Limited | -87.95 Million USD | 95.658% |
| Marizyme, Inc. | -65.34 Million USD | 94.156% |
| Genus plc | 7.9 Million USD | 148.342% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 64.937% |
| Pharming Group N.V. | -10.54 Million USD | 63.794% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -76.006% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -2.932% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 56.818% |
| ContraFect Corporation | -65.15 Million USD | 94.138% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 21.839% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -121.077% |
| IMV Inc. | -36.48 Million USD | 89.533% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 52.616% |
| MultiCell Technologies, Inc. | -380.07 USD | -1004714.903% |
| ONE Bio Corp. | 8.67 Million USD | 144.015% |
| Accustem Sciences Inc. | -3.74 Million USD | -1.937% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 92.612% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -201.389% |
| Q BioMed Inc. | -2.05 Million USD | -86.103% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -2.304% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -60.404% |
| Biomind Labs Inc. | -1.21 Million USD | -214.497% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 93.606% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -23.123% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 51.677% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -95.922% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -25400.801% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 75.938% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 34.35% |
| GB Sciences, Inc. | -1.36 Million USD | -180.463% |
| Alpha Cognition Inc. | -13.77 Million USD | 72.271% |
| HST Global, Inc. | -146.21 Thousand USD | -2511.996% |
| CSL Limited | 2.64 Billion USD | 100.145% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -117.635% |
| Halberd Corporation | -79.67 Thousand USD | -4693.162% |
| Enzolytics Inc. | -2.17 Million USD | -75.438% |
| Agentix Corp. | -1.37 Million USD | -177.905% |
| Resverlogix Corp. | -3.61 Million USD | -5.789% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -20.419% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.706% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3996.939% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 155.151% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 3.876% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -26.201% |
| AVAX Technologies, Inc. | -6.41 Million USD | 40.455% |
| Zenith Capital Corp. | -10.59 Million USD | 63.958% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.0% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -16331.46% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 7.886% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -6218.599% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -90.463% |
| Kadimastem Ltd | -3.3 Million USD | -15.468% |
| Helix BioMedix, Inc. | -1.05 Million USD | -261.628% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 54.98% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -765.262% |
| LadRx Corporation | 400.44 Thousand USD | 1053.694% |
| Cell Source, Inc. | -5.32 Million USD | 28.231% |
| Regen BioPharma, Inc. | 1.02 Million USD | 473.128% |
| Regen BioPharma, Inc. | 1.02 Million USD | 473.128% |
| NovAccess Global Inc. | -4.76 Million USD | 19.923% |
| Affymax, Inc. | -14.42 Million USD | 73.523% |
| Itoco Inc. | -1.86 Million USD | -104.334% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 14.036% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -128.82% |
| Mobile Lads Corp. | -2.26 Million USD | -68.737% |
| CytoDyn Inc. | -49.84 Million USD | 92.338% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -4732.159% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1574.068% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -305.617% |
| SYBLEU INC | -180.3 Thousand USD | -2018.089% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -136.802% |
| International Stem Cell Corporation | -131 Thousand USD | -2815.267% |
| Bioxytran, Inc. | -4.28 Million USD | 10.771% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -6936.778% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -50.934% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 92.056% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -80.653% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -389.059% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -20.549% |
| Neutra Corp. | -233.46 Thousand USD | -1535.791% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 81.179% |
| PureTech Health plc | -65.69 Million USD | 94.187% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 82.042% |
| IXICO plc | -1.17 Million USD | -224.194% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 61.529% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 93.315% |
| CSL Limited | 2.64 Billion USD | 100.145% |
| Cellectis S.A. | -103.17 Million USD | 96.298% |